Cerus Corporation (NASDAQ:CERS) announced today that it will postpone
its scheduled release date for its third quarter financial results from
Tuesday, October 30, 2012 to Wednesday, November 7, 2012, after the
close of the stock market.
“Given the significant impact Hurricane Sandy has had and is expected to
continue to have along the eastern coast of the U.S., we have decided to
postpone the release of our third quarter financial results in order to
ensure that all members of the investment community have the opportunity
to access our results,” said William “Obi” Greenman, Cerus’ president
Cerus will host a conference call and webcast accordingly at 4:15 PM EDT
on November 7, 2012, during which management will discuss the Company’s
financial results and provide a general business overview and outlook.
To access the live webcast, please visit the Investor Relations page of
the Cerus web site at http://investor.cerus.com/Investors/Investor-Overview.
Alternatively, you may access the live conference call by dialing
866-235-9006 (U.S.) or 631-291-4549 (international).
A replay will be available on the company’s web site, or by dialing
855-859-2056 (U.S.) or 404-537-3406 (international) and entering
conference ID number 63119758. The replay will be available
approximately three hours after the call through November 21, 2012.
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action enables
INTERCEPT treatment to inactivate established transfusion threats, such
as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed
to inactivate emerging pathogens such as influenza, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the
world. The INTERCEPT red blood cell system is in clinical development.
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus